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TETRACYCLINES AND FETAL BONES*
HAROLD M . FROST**

I : iNTRODEfCTION

The tetracycline group of antibiotics has attracted considerable interest because
of a property incidental to the usefulness in combating infections: The ability
to deposit in mineralizing, newly formed organic matrices, and to remain
there for long periods of time afterwards.^" This has led to the investigational use of
this class of drugs as markers in time deposited in vivo in the mineralized parts of the
slceleton.2"'"'1'"'" (See figure 1). Large numbers of people in the United States
have received one or more courses of treatment with these agents since the first
(Aureomycin) was marlseted in 1950. In a survey in 1961 of bones systematically
collected from the operating and postmortem rooms of Henry Ford Hospital,
Sedlin found that 46 per cent of some 460 patients had received the drug one or
more times." This large relative incidence of receipt of the drug may be attributed
in part to its broad spectrum of bacterial effectiveness, and in part to the fact that
it can be given orally and so is convenient to administer.
The concern of obstetricians and gynecologists over this in vivo deposition centers
on the fact that the tetracyclines can cross the placental barrier as well as the cell
membrane with ease, and so they can and do enter the fetal circulation.'" " Interest
properly focusses on four points: teratogenesis*, interference with postnatal development, the fate and effect of tetracycline labelled bone and cartilage, and the fate
and effect of labelled teeth. These four matters will be discussed briefly next, and
in the order just given.
I I : TERATOGENESIS*

The thalidomide catastrophe effectively alerted all who prescribe drugs to the
possibility that unpredictable, harmful effects on the developing embryo and fetus
can be exerted by otherwise innocuous agents. Furthermore, an agent may have
*Paper read before the Midwest Association of Obstetricians and Gynecologists, Henry Ford
Hospital, March 1965.
**Associate Orthopedic Surgeon. The experience that permitted me to give this talk was made
possible by aid given by Grants 293, Henry Ford Hospital; AM-04186, National Institutes of
Health; and O.R.E.F., 1962. I am also deeply indebted to C. L. Mitchell, J. D. Godfrey and
D. M . Bosworth for other kinds of aid without which this work would not have been done. I am
grateful to Dr. Bruce Epker for help in preparing the manuscript.
*Meaning interference with embryonic or fetal development (Dorland's Medical Dictionary).
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Figure 1
A fluorescence photomicrograph of a mineralized cross section of bone from a man, who had been
given several courses of tetracyclines during the treatment of a chronic osteomyelitis. The bright
rings are the tetracyclines, glowing by virtue of the short wave length light shining on them. They
are almost exactly like growth rings in a tree, and can be used for purposes of making measurements
when the time and duration of administration of the drug are known.
serious effects on human embryos, and none on those of mice, rats, hamsters,
rabbits, dogs, pigs, monkeys, and conversely. This makes it impossible to assure
safety of a new drug solely on the basis of animal testing.
Teratogenic effects may be exerted by compounds normally present in the
body, as well as by those foreign to it. Both insulin and cortisone, for example,
can be highly teratogenic under the right circumstances. Teratogenesis usually
requires two essential things: (/) the presence of abnormal concentrations of a
teratogenic agent; {ii) which must occur at the right moment in intrauterine life.
The development of the embryo proceeds through many separate stages or steps, each
stage occurring at a certain moment in intrauterine life. An agent, when given
during the 12th week of pregnancy, may cause a given fetal abnormality 70 per cent
of the time, but when given on the 14th or later week may cause no abnormality.
The reasons for this kind of behavior are presumably related to the peculiar geometrical
and chemical properties of the agent in the body fluids, which by chance enable
it to act like an antimetabolite at one specific step in the chain of cellular differentiations essential to the normal development of the embryo.
In the doses usually given adults orally for the treatment of infections in man,
the tetracycline group of antibiotics axe not known to be teratogenic to the embryo
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or fetus. However, when given in very high dosages (which has usually involved
intravenous administration), several kinds of developmental abnormalities have been
observed in a number of developing animal embryos and fetuses in a number of
animal species."' '"'^' Retardation of longitudinal bone growth has been reported in
children (i.e., postnatally) treated with high, prolonged dosages of these agents, but
this was reversible in that when the drugs were stopped, normal and apparently unimpaired growth resumed.' It may be significant in this respect that the tetracyclines
are known to impair protein synthesis in microorganisms."
In sum, there does not seem to be any contraindication to giving a tetracycline
antibiotic to a pregnant woman from the purely teratogenic standpoint, as long as
recommended dosages are adhered to. (But see below under Teeth). High dosages,
such as in excess of 1.5 grams/day (i.e., 20 mg/kilo/day) intravenously, may prove
to be unwise.
Ill:

INTERFERENCE W I T H POSTNATAL DEVELOPMENT

There are no instances known to me in which giving a tetracycline antibiotic
to a pregnant woman has caused a postnatal developmental abnormality tO' occur in
her child. (But see below under Teeth; perhaps this is splitting a terminological or
semantic hair).
IV:

TETRACYCLINE LABELLING OF BONE AND CARTILAGE

In the fetal skeleton, there are four basic kinds of mineralized tissue. One,
the Teeth, will be considered separately and last. The other three kinds are hyaline
cartilage, which is involved primarily in longitudinal growth of the bones; fibrous or
woven bone, which is involved primarily in the longitudinal growth of the bones;
and lamellar bone, which is the end product of the complex series of cellular events
involved in bone growth and development, and which is the stuff of which adult
skeletons are almost wholly made.' ' " ^'
All three of these tissues have these features in common: they have an organic
matrix made by specialized kinds of cells (chondroblasts and osteoblasts, see
figure 2), and composed of collagen fibers embedded in cementing substances, much
like bundles of string embedded in gelatin. After the organic matrix has been made,
it then begins to mineralize or calcify by the deposition in it of crystals of inorganic
bone salts (largely calcium hydroxyapatite).
The tetracycline antibiotics "label", or deposit in, mineralizing or mineralized
tissues in two basically different ways.' " ( / ) The tetracycline molecule can
become adsorbed or "stuck" on any calcified surface. This is a reversible, temporary
process. Tetracycline attached to the surfaces of mineralized tissues in this manner
disappears (quantitatively for practical purposes) within three days of stoppage of
the drug. The drug is excreted from the body in the urine and feces, and some
of it is degraded in the liver.' (/;) The tetracyclines can deposit with the mineral
and be incorporated inside the mineralized tissue, where any newly made organic
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Figure 2
A group of osteoblasts are shown as they appear in decalcified, microtome-cut thin sections (i.e.,
conventionally prepared). These are the specialized cells that make the new organic part of bone,
and a number of them in the field that is shown have in fact surrounded themselves with new
organic matrix. Cells that have thus "buried" themselves change their function and are called
osteocytes; they may live for many years in their small bony holes, which are called lacunae.

matrix is actively mineralizing. A different kind of physical-chemical phemonenon
is involved in this type of skeletal labelling, which is permanent in that the label
stays until the labelled tissue is subsequently resorbed by cellular activity.'" Thus
a person who is given a tetracycline antibiotic will deposit a tetracycline label at
every place in his skeleton where he was making and mineraUziiig new bone or
cartilage during the time the drug was in his blood. Such labels have been found
in the skeleton by us more than 11 years after their deposition, and there is every
reason to expect that many of them will still be present after 30 years or more.
Now, the adsorbed or temporary label is all gone, insofar as fluorescence or
chemical analytic methods can determine, within three days of stopping the drug."
Thus there seems to be no permanent labelling, and no risk of any later harm to
cells, from this source, be it to the mother or the fetus. The permanent label is
locked away inside mineralized tissue, well isolated from the cells in the body,
so that the drug in this kind of label cannot later affect them either. Even
when a bit of labelled bone is subsequently resorbed so that its label is returned
to the blood, the tetracycline in it is diluted in the body's total pool of extracellular
and intracellular water, which in effect is more than 10' (i.e., one billion times)
larger than the volume of tissue in which the tetracycline label lay before it was
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resorbed. Thus, resorption of labelled tissue will produce only infinitesimal concentrations of the drug in the body fluids, although they will be maintained for some
considerable time after drug administration, due to the continued turnover of the
skeleton throughout life.
In the case of the fetus, the initial amount of tetracycline incorporated into the
developing skeleton will be much larger per gram of skeletal tissue than in the
mother's skeleton,* because of the much more active bone formation going on in
the fetus, again on a per gram of skeletal tissue basis. The embryo will not begin
to deposit much tetracycline until about the 12th week, when calcificaticn of hyaline
cartilage begins to be important in the development of the skeleton. While there is
much more tetracycline per gram of bone (and cartilage) in the fetus than in the
mother, this is still physically and essentially totally immobilized in the bone salt,
and so as long as it stays there it cannot affect the cells of an embryo or fetus, or
even microorganisms. When this labelled material is subsequently resorbed, as it will
and must be, the tetracycline in it is diluted not only by the fetal and amniotic fluid
reservoir, but also via the maternal circulation by the mother's pool of body water,
because the drug passes as readily from fetus to mother as the other way.
These facts mean that the normal process of cellular removal of tetracycline
labelled bone and cartilage cannot cause blood concentrations of tetracyclines that
even remotely approach those that exist when the drug is given during active treatment.
So whatever risk may be involved in giving the drugs would seem (to me at least)
to be limited to the time during which it is being given, because the concentrations
in the body fluids then are many orders of magnitude larger than those which result
from resorption of previously labelled tissue.
And the actual facts, as presently known, with respect to the above points are:
No known harmful effect on human skeletal development results in the embryo
or fetus from treating a pregnant woman with usually recommended doses of a
tetracycline antibiotic. No known harmful effect follows resorption of tetracycline
labelled skeletal tissue in the embryo, fetus, mother or infant. There are harmful
effects of giving too much tetracycline (particularly hepatotoxic effects),'*'''''^' but in
this respect the drugs are not different from insulin, vitamin D or cortisone,
all compounds that are useful and essential, but harmful and even teratogenic,
when given in too large doses.
V:

TEETH

Like hyaline cartilage and bone, teeth are composed of a mineralized organic
matrix, the matrix being formed by special kinds of cells." There are really three
kinds of mineralized matrix in teeth, named cementum, dentin and enamel. With
respect to tetracycline labelling of these tissues, there are two kinds here too:
(/) The tetracyclines can adsorb or stick to the mineralized exposed surface.
As in bone this is reversible or temporary, and surface-adsorbed drug dis*By a factor of more than 100.
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appears entirely within a few days of stopping the drug, (ii) The tetracyclines
can also deposit with the mineral when each of these three kinds of matrix is
beginning to mineralize. This occurs soon after they have been made by the specialized
cells that are involved in making teeth. And as in bone, this kind of label is
permanent. Unlike bone, teeth are not subject to significant resorption, so that
tetracycline deposited in teeth may be considered to be permanently and totally
removed from the body fluids and any access to cells. As in bone, a tetracycline label
has a canary yellow color which is easily visible in a labelled tissue exposed to
daylight. Since bone and cartilage are buried deep in the body, their labels cannot
be seen from the outside of the body. But teeth are exposed and visible, and
therefore their labels can be seen with the naked eye.^ " "
Cementum covers the root of the tooth, which is buried within the jaw bones
and so its abnormal coloration caused by a tetracycline label is of no cosmetic
importance. Dentin occurs inside the tooth; when labelled with tetracycline its
canary yellow color may be seen shining through the overlying enamel, provided the
label was laid down early in the formation of the tooth. I f the label is buried too
deeply in the dentine to be visible from the outside (which happens when it is
deposited towards the end of dentin formation), it is of no cosmetic importance. The
enamel is the outer, exposed layer of mineralized tissue in a tooth; it is what we see
direcdy. Tetracycline deposited in this layer is also a canary yellow color initially,
but oxidation products occur which tend subsequently to turn it brown, producing
a noticeably and sometimes objectionably discolored tooth. This may be only of
temporary concern if it occurs in the primary teeth, since they will be shed and
replaced, but it is objectionable if it occurs in the permanent teeth. The enamel
of the first permanent teeth to develop begins to mineralize in about the last two
months of pregnancy, and continues to do so in one or another tooth until about
age five. Thus a woman receiving a tetracycline in the last trimester of pregnancy
may bear a child whose permanent teeth (usually incisors, cuspids, and/or first
molars), when they erupt six or more years later, will show a cosmetically objectionable
discoloration.
So, do not give tetracyclines to women in their last trimester, unless there are
compelling reasons for doing so, and in that event the parents should be forewarned
about the possibility of coloration of the child's permanent teeth.
Is the labelling of teeth harmful to the function of the teeth? No; it is objectionable on cosmetic grounds only. The visibility of a label in a tooth will depend on
the dose level of the drug and on its duration. I f the drugs are given for only a few
days and in moderate doses, it is likely that no visible label will result; however, this
cannot be depended on.
Is the development of teeth affected by the tetracyclines? The answer is a
qualified yes. Unlike the case for bone, occasionally enamel hypoplasia, or imperfect
development of the outer, mineralized layer of the tooth, occurs following intensive
treatment, usually for prolonged periods, with a tetracycline antibiotic given during
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the development of the teeth. I f the involved tooth is a deciduous (i.e., primary)
one, it will later be replaced by a permanent one with no permanent harm done.
But if the involved tooth is a permanent one, the defect is permanent and can be
functionally troublesome, since hypoplastic teeth do not last or stand up normally.
How

ARE TETRACYCLINES STUDIED WHEN DEPOSITED IN MINERALIZED TISSUES?

The tetracyclines can fluoresce. That is, when light of short wave length (i.e.,
ultraviolet or blue light) shines on anhydrous tetracycline, some of the energy in this
light is reemitted by the tetracycline molecules as light of longer wave length (i.e.,
more red). By using suitable blocking filters, the light in the exciting light source
can be kept from the eye (or f i l m ) , while the light from the fluorescence of the
tetracycline is allowed to pass. This is usually done with fluorescence microscopes.''
The labelled bone or tooth has to be prepared in the form of undecalcified sections
for this kind of study because the conventional processing of mineralized tissues for
histological sectioning removes the tetracycline as well as the calcium.'" With the
fluorescence microscope, the tetracycline labels appear as golden yellow bands or
patches in the tissue. They are being studied intensively by scientists interested in
the physiology of mineralized tissue, because they provide a marker in time, deposited
in vivo, which allows the amount of new tissue made in a known length of time
to be measured, and which allows one to detect every place where such new tissue
was being formed, even months or years after the labelling event.'"''^'"'"''"'"'™''""
In effect, bone and teeth are records of what cells did. These records can be partially
translated, in good part because of the help we have received by using the tetracycline
antibiotics as markers in time. The bone and tooth record has these attributes:
(f) one can study cell function rather than appearance or composition, (if) this
function occurs in vivo under completely natural conditions, and {Hi) the act of
observing it cannot disturb the ceUs being studied because the act occurs after the
function being measured has occurred.'"
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